- Home
- FRPH vs FDMT Comparison
FRPH vs FDMT Comparison
Compare FRPH & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRPH | FDMT |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 431.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRPH | FDMT |
|---|---|---|
| Price | $23.86 | $8.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $34.29 |
| AVG Volume (30 Days) | 60.8K | ★ 792.0K |
| Earning Date | 03-04-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $33,049,999.00 | $120,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $97.90 | ★ N/A |
| Revenue Growth | 5.21 | ★ 605.88 |
| 52 Week Low | $21.68 | $2.24 |
| 52 Week High | $31.99 | $12.34 |
Technical Indicators
Market Signals| Indicator | FRPH | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 47.43 |
| Support Level | $23.42 | $7.30 |
| Resistance Level | $24.62 | $7.80 |
| Average True Range (ATR) | 0.53 | 0.54 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 61.14 | 59.62 |
Price Performance
Historical ComparisonAbout FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.